As depicted in Table 5, 57.1% of patients with SS received 5-HT2A antagonist compared to 8.8% of patients without SS (p < 0.001), summing up to 17.9% of the studied patients (n = 20). This evidence concerns the gene HTR2A and synovial sarcoma.